Biologics Regulatory Sports Medicine Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® byTim AllenApril 29, 2026
Financial Recon Robotics Hip Replacement Market to Reach US$ 11.4 Billion by 2033 Driven by Aging Population, Rising Osteoarthritis, and Robotic-Assisted Surgery Says Astute Analytica byJosh SandbergFebruary 2, 2026
Regulatory Sports Medicine Top Stories FDA Approves Updated Label for Miach Orthopaedics’ BEAR® Implant to Include Significantly Lower Risk of Osteoarthritis byJosh SandbergJanuary 14, 2026
Biologics Extremities Spine Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care byJosh SandbergDecember 19, 2025
Regulatory Sports Medicine Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain byTim AllenDecember 15, 2025
Recon New Lancet-Published Study Shows AI-Powered Decision Support Tool Improves Decision Quality and Patient Outcomes byTim AllenDecember 10, 2025
Neuro Sports Medicine SPRI and Neuromuscular Dynamics Launch NIH-Funded Clinical Trial to Advance Non-Surgical Knee Osteoarthritis Treatment byTim AllenNovember 18, 2025
Regulatory Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee byJosh SandbergOctober 28, 2025
Extremities Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy byJosh SandbergOctober 21, 2025
Biologics Regulatory Doron Therapeutics Announces First Patients Dosed in Phase 3 Study of MOTYS (PTP-001) for the Treatment of Osteoarthritis of the Knee byTim AllenOctober 17, 2025
